ClinicalTrials.gg
CompletedNCT04456842LACROSSUpdated Oct 4, 2024

Cardiovascular Registry of Atrial Fibrillation

An observational study in Atrial Fibrillation and Atrial Flutter, sponsored by Brazilian Clinical Research Institute. Completed at 17 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by Brazilian Clinical Research Institute · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,016
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Atrial Fibrillation with a site in Argentina — 5 open to participants now, 6 under way, 2 of them phase 3. Atrial Fibrillation · Argentina.

Enrollment
5th of 12
2,016 · median 1,266
Started
2020
with 2 others
Observational
12 of 45
2 open now
Registered
36th of 45
by date

Among the 45 studies in Atrial Fibrillation with a site in Argentina, this one is the 5th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2020, is one of 12 observational ones, and was the 36th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

5 of the 45 studies in Atrial Fibrillation with a site in Argentina are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Atrial Fibrillation with a site in Argentina, or all of them as a file.
02

Study summary

Follow a representative sample of Latin American patients diagnosed with atrial fibrillation to set data on demographic characteristics, documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death

Read the detailed description

Patients will be followed 6 months and 1 year after the baseline visit and will be collected data of antithrombotic therapy, laboratory data, discontinuation rates of antithrombotic therapy and clinical outcomes.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Flutter

Keywords

  • Atrial Fibrilation
  • Antithrombotic therapy
  • Atrial Flutter
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patient with Atrial Fibrilation or Atrial Flutter

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years-old that signed ;
  • Atrial Fibrillation or Atrial Flutter at the time of inclusion documented in source document;
  • If the patient is not in atrial fibrillation or Atrial Flutter rhythm, s/he should have 2 electrographic records, at least 15 days apart between them, with one of them being performed within the last 6 months before enrollment (AF may be documented by 12-lead , Holter monitor-24h);

Exclusion criteria

Exclusion Criteria:

  • Patients who did not agree to participate.
  • Patients without possibility of monitoring for one year.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,016 participants (actual)
Target follow-up
12 Months
Patient registry
Yes

Interventions

  • OtherPatient Registry Data

    To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.

06

What researchers measure

Primary outcomes

  1. INR control rate

    Time frame: 12 months

  2. Oral anticoagulation discontinuation rate

    Time frame: 12 months

  3. Percentage of death

    Time frame: 12 months

  4. Percentage of stroke

    Time frame: 12 months

  5. Percentage of systemic embolism

    Time frame: 12 months

  6. Percentage of myocardial infarction

    Time frame: 12 months

  7. Percentage of major bleeding

    Time frame: 12 months

  8. Percentage of electrical cardioversion

    Time frame: 12 months

  9. Percentage of percutaneous ablation of AF

    Time frame: 12 months

  10. Percentage of atrioventricular junction ablation

    Time frame: 12 months

  11. Percentage of patients that need of pacemaker implantation

    Time frame: 12 monts

  12. Percentage of other cardiovascular hospitalization

    Time frame: 12 months

07

Study locations

17 sites
  • Hospital Interzonal General de Agudos "Dr. José Penna"
    Bahía Blanca, Buenos Aires, Argentina
  • DIM Clínica Privada
    Ramos Mejía, Buenos Aires, Argentina
  • Centro de Investigaciones Medicas Temperley (CIMeT)
    Temperley, Buenos Aires, Argentina
  • Hospital Italiano de La Plata
    Buenos Aires, La Plata, Argentina
  • Centro Modelo de Cardiologia
    San Miguel De Tucumán, Tucumán, Argentina
  • Centro Medico Luquez
    Córdoba, Argentina
  • Prevención Cardiovascular Salta
    Salta, Argentina
  • Servicios Médicos El Castaño
    San Juan, Argentina
  • Instituto Cardiovascular San Luis
    San Luis, Argentina
  • Centro de Investigaciones Clinicas del Litoral SRL
    Santa Fe, Argentina
  • Hospital Provincial Dr. José Maria Cullen
    Santa Fe, Argentina
  • Hospital Alvorada Taguatinga Ltda
    São Paulo, Brazil
  • Sociedad de Cirugia de Bogota - Hospital de San Jose
    Bogotá, Cundinamarca, Colombia
  • Fundacion Valle del Lili
    Cali, Valle Del Cauca, Colombia
  • Francisco Gerardo Padilla Padilla
    Guadalajara, Jalisco, Mexico
  • Centro de Estudios Clínicos de Queretaro S.C. (CECLIQ)
    Querétaro City, Querétaro, Mexico
  • Centro para el Desarrollo de la Medicina y de Asistecia Medica Especializada S.C.
    Culiacán, Sinaloa, Mexico
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2024, 49 months.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 49 months is close to that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jul 7, 2020
StartActual
Aug 4, 2020
Primary completionActual
Sep 13, 2024
CompletionActual
Sep 30, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04456842
Lead sponsor
Brazilian Clinical Research Institute
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Aug 4, 2020
Primary completion
Sep 13, 2024
Completion
Sep 30, 2024
Last update
Oct 4, 2024

Study contacts

Renato D. Lopes, MD, PhD
study chair · Instituto Brasileiro de Pesquisa Thomaz de Carvalho - BCRI

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion